(Q30365764)

English

Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 June 2017

Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans. (English)

1 reference

Europe PubMed Central

21 June 2017

toll-like receptor

0 references

1 reference

based on heuristic

inferred from title

influenza vaccine

1 reference

based on heuristic

inferred from title

author name string

Edgar Turner Overton

1

1 reference

Europe PubMed Central

21 June 2017

Paul A Goepfert

2

1 reference

Europe PubMed Central

21 June 2017

Pamela Cunningham

3

1 reference

Europe PubMed Central

21 June 2017

William A Carter

4

1 reference

Europe PubMed Central

21 June 2017

Joseph Horvath

5

1 reference

Europe PubMed Central

21 June 2017

Diane Young

6

1 reference

Europe PubMed Central

21 June 2017

David R Strayer

7

1 reference

Europe PubMed Central

21 June 2017

language of work or name

0 references

publication date

13 August 2014

1 reference

Europe PubMed Central

21 June 2017

1 reference

Europe PubMed Central

21 June 2017

32

1 reference

Europe PubMed Central

21 June 2017

42

1 reference

Europe PubMed Central

21 June 2017

5490-5495

1 reference

Europe PubMed Central

21 June 2017

The annual impact of seasonal influenza in the US: Measuring disease burden and costs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.078

7 January 2021

TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not Poly(I:C): differential recognition of synthetic dsRNA molecules

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.078

7 January 2021

Toll-like receptor 3 is induced by and mediates antiviral activity against rhinovirus infection of human bronchial epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.078

7 January 2021

Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.078

7 January 2021

Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.078

7 January 2021

Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.078

7 January 2021

A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.078

7 January 2021

The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.078

7 January 2021

Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.078

7 January 2021

Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.078

7 January 2021

Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.078

7 January 2021

Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.078

7 January 2021

Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.078

7 January 2021

Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.078

7 January 2021

Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.078

7 January 2021

Localized mucosal response to intranasal live attenuated influenza vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.078

7 January 2021

Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.078

7 January 2021

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.078

7 January 2021

Identifiers

10.1016/J.VACCINE.2014.07.078

1 reference

Europe PubMed Central

21 June 2017

1 reference

Europe PubMed Central

21 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30365764&oldid=1550106869"